221 related articles for article (PubMed ID: 22673317)
1. Increased oxidized-LDL levels and arylesterase activity/HDL ratio in ESRD patients treated with hemodialysis.
Mahrooz A; Zargari M; Sedighi O; Shaygani H; Gohari G
Clin Invest Med; 2012 Jun; 35(3):E144-51. PubMed ID: 22673317
[TBL] [Abstract][Full Text] [Related]
2. Serum paraoxonase phenotype distribution in exudative age-related macular degeneration and its relationship to homocysteine and oxidized low-density lipoprotein.
Javadzadeh A; Ghorbanihaghjo A; Bahreini E; Rashtchizadeh N; Argani H; Alizadeh S
Retina; 2012 Apr; 32(4):658-66. PubMed ID: 22030834
[TBL] [Abstract][Full Text] [Related]
3. Association between moderately oxidized low-density lipoprotein and high-density lipoprotein particle subclass distribution in hemodialyzed and post-renal transplant patients.
Kimak E; Hałabiś M; Baranowicz-Gąszczyk I; Solski J; Książek A
J Zhejiang Univ Sci B; 2011 May; 12(5):365-71. PubMed ID: 21528490
[TBL] [Abstract][Full Text] [Related]
4. Positive association between plasma levels of oxidized low-density lipoprotein and myeloperoxidase after hemodialysis in patients with diabetic end-stage renal disease.
Kitabayashi C; Naruko T; Sugioka K; Yunoki K; Nakagawa M; Inaba M; Ohsawa M; Konishi Y; Imanishi M; Inoue T; Itabe H; Yoshiyama M; Haze K; Becker AE; Ueda M
Hemodial Int; 2013 Oct; 17(4):557-67. PubMed ID: 23627905
[TBL] [Abstract][Full Text] [Related]
5. Serum paraoxonase activity in uremic predialysis and hemodialysis patients.
Dirican M; Akca R; Sarandol E; Dilek K
J Nephrol; 2004; 17(6):813-8. PubMed ID: 15593056
[TBL] [Abstract][Full Text] [Related]
6. Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human serum paraoxonase in patients with type 2 diabetes.
Tsuzura S; Ikeda Y; Suehiro T; Ota K; Osaki F; Arii K; Kumon Y; Hashimoto K
Metabolism; 2004 Mar; 53(3):297-302. PubMed ID: 15015140
[TBL] [Abstract][Full Text] [Related]
7. Paraoxonase 1 activity and level of antibodies directed against oxidized low density lipoproteins in a group of an elderly population in Poland - PolSenior study.
Bednarska-Makaruk M; Rodo M; Szirkowiec W; Mossakowska M; Puzianowska-Kuźnicka M; Skalska A; Zdrojewski T; Ryglewicz D; Wehr H
Arch Gerontol Geriatr; 2015; 60(1):153-61. PubMed ID: 25459919
[TBL] [Abstract][Full Text] [Related]
8. Activity of paraoxonase 1 (PON1) and its relationship to markers of lipoprotein oxidation in healthy Slovaks.
Sumegová K; Blazícek P; Waczulíková I; Zitnanová I; Duracková Z
Acta Biochim Pol; 2006; 53(4):783-7. PubMed ID: 17106515
[TBL] [Abstract][Full Text] [Related]
9. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants.
Aviram M; Rosenblat M; Billecke S; Erogul J; Sorenson R; Bisgaier CL; Newton RS; La Du B
Free Radic Biol Med; 1999 Apr; 26(7-8):892-904. PubMed ID: 10232833
[TBL] [Abstract][Full Text] [Related]
10. Hypochlorous acid and low serum paraoxonase activity in haemodialysis patients: an in vitro study.
Sutherland WH; de Jong SA; Walker RJ
Nephrol Dial Transplant; 2004 Jan; 19(1):75-82. PubMed ID: 14671042
[TBL] [Abstract][Full Text] [Related]
11. Paraoxonase-1 (PON1) activity as a risk factor for atherosclerosis in chronic renal failure patients.
Saeed SA; Elsharkawy M; Elsaeed K; Fooda O
Hemodial Int; 2008 Oct; 12(4):471-9. PubMed ID: 19090870
[TBL] [Abstract][Full Text] [Related]
12. The platelet activating factor acetyl hydrolase, oxidized low-density lipoprotein, paraoxonase 1 and arylesterase levels in treated and untreated patients with polycystic ovary syndrome.
Carlioglu A; Kaygusuz I; Karakurt F; Gumus II; Uysal A; Kasapoglu B; Armutcu F; Uysal S; Keskin EA; Koca C
Arch Gynecol Obstet; 2014 Nov; 290(5):929-35. PubMed ID: 24840107
[TBL] [Abstract][Full Text] [Related]
13. Paraoxonase activity in healthy, diabetic, and hemodialysis patients.
Gbandjaba NY; Ghalim N; Hassar M; Berrougui H; Labrazi H; Taki H; Saile R; Khalil A
Clin Biochem; 2012 Apr; 45(6):470-4. PubMed ID: 22285382
[TBL] [Abstract][Full Text] [Related]
14. Serum paraoxonase 1 (PON1) lactonase activity is lower in end-stage renal disease patients than in healthy control subjects and increases after hemodialysis.
Gugliucci A; Kinugasa E; Kotani K; Caccavello R; Kimura S
Clin Chem Lab Med; 2011 Jan; 49(1):61-7. PubMed ID: 20961187
[TBL] [Abstract][Full Text] [Related]
15. Alterations of paraoxonase and platelet-activating factor acetylhydrolase activities in patients on peritoneal dialysis.
Liberopoulos EN; Papavasiliou E; Miltiadous GA; Cariolou M; Siamopoulos KC; Tselepis AD; Elisaf MS
Perit Dial Int; 2004; 24(6):580-9. PubMed ID: 15559488
[TBL] [Abstract][Full Text] [Related]
16. Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis.
Navarro JF; Mora C; Muros M; García-Idoate G
Nephron Clin Pract; 2003; 95(4):c128-35. PubMed ID: 14694274
[TBL] [Abstract][Full Text] [Related]
17. Higher Levels of Oxidized Low Density Lipoproteins in Alzheimer's Disease Patients: Roles for Platelet Activating Factor Acetyl Hydrolase and Paraoxonase-1.
Bacchetti T; Vignini A; Giulietti A; Nanetti L; Provinciali L; Luzzi S; Mazzanti L; Ferretti G
J Alzheimers Dis; 2015; 46(1):179-86. PubMed ID: 25720407
[TBL] [Abstract][Full Text] [Related]
18. Activity of paraoxonase 1 (PON1) on HDL
Miljkovic M; Stefanovic A; Vekic J; Zeljkovic A; Gojkovic T; Simic-Ogrizovic S; Bogavac-Stanojevic N; Cerne D; Ilic J; Stefanovic I; Jelic-Ivanovic Z; Spasojevic-Kalimanovska V; Kotur-Stevuljevic J
Clin Biochem; 2018 Sep; 60():52-58. PubMed ID: 30130521
[TBL] [Abstract][Full Text] [Related]
19. Association of Serum Paraoxonase/Arylesterase Activity With All-Cause Mortality in Maintenance Hemodialysis Patients.
Suematsu Y; Goto M; Park C; Nunes ACF; Jing W; Streja E; Rhee CM; Cruz S; Kashyap ML; Vaziri ND; Narayanaswami V; Kalantar-Zadeh K; Moradi H
J Clin Endocrinol Metab; 2019 Oct; 104(10):4848-4856. PubMed ID: 30920627
[TBL] [Abstract][Full Text] [Related]
20. Influence of single hemodialysis session on serum paraoxonase-1, arylesterase activity, total oxıdant status and total antioxidant status.
Yildiz G; Aydin H; Mağden K; Yilmaz A; Hür E; Candan F
Minerva Med; 2014 Feb; 105(1):79-87. PubMed ID: 24572453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
